Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1457006
This article is part of the Research Topic Biomarker Discovery and Therapeutic Innovations in Genito-Urinary Cancer Management View all 7 articles

Treatment Approaches in Advanced Penile Cancer: Targeted Therapies and Immunotherapy

Provisionally accepted
David J. Benjamin David J. Benjamin 1*Robert C. Hsu Robert C. Hsu 2
  • 1 Hoag Family Cancer Institute, Irvine, United States
  • 2 Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States

The final, formatted version of the article will be published soon.

    Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or metastatic disease. With the emergence of immune checkpoint inhibitors and targeted therapies for specific genomic aberrations in the treatment of over a dozen other cancers, recent studies have sought to identify therapies other than chemotherapy in treating this uncommon cancer. Several ongoing trials involving immune checkpoint inhibitors, tyrosine kinase inhibitors, and antibody drug conjugates are attempting to identify additional therapies.

    Keywords: Penile Cancer, targeted therapy, Immune checkpoint inhibitor, Antibody drug conjugate, Vaccine

    Received: 29 Jun 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Benjamin and Hsu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: David J. Benjamin, Hoag Family Cancer Institute, Irvine, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.